ALK
resistance mutations are more common
after failure of 2nd generation ALK TKIs
Gainor, et al. Cancer Discov 2016
Crizotinib
n=55
Ceritinib
n=24
91% prior crizotinib
Alectinib
n=17
100% prior crizotinib
L1196M
G1269A
C1156Y
I1171T/N/S
G1202R
G1202del
F1174C
V1180L
S1206Y
E1210K
≥2 ALK mutations
ALK amplification
ALK WT
